{'fraction_non_alphanumeric': 0.01893939393939394, 'fraction_numerical': 0.008522727272727272, 'mean_word_length': 5.732484076433121, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Atrial natriuretic peptide and angiotensin II interaction on noradrenaline uptake in the central nervous system.

The effects of different concentrations of atrial natriuretic peptide and angiotensin II on [3H]-noradrenaline uptake in hypothalamus and medulla oblongata slices incubated in vitro were determined. Atrial natriuretic peptide, in a dose of 100 mM, increased [3H]-noradrenaline uptake in both regions, while 1 microM of angiotensin II had the opposite effect. The ineffective concentration of 1 nM atrial natriuretic peptide reversed the action of 1 microM of angiotensin II on [3H]-noradrenaline uptake, whereas ineffective concentrations of angiotensin II failed to modify atrial natriuretic peptide effects. These results are compatible with the existence of an atrial natriuretic peptide-angiotensin II interaction in the central nervous system and with the hypothesis that some of the hypotensive effects of atrial natriuretic peptide could occur through modulation of an angiotensin-noradrenergic mechanism in the central nervous system.